By Counterforce Health Team in Tracleer (bosentan) —

How to Get Tracleer (bosentan) Covered by Aetna (CVS Health) in New York: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Tracleer (bosentan) Covered by Aetna (CVS Health) in New York

Aetna (CVS Health) requires prior authorization and typically step therapy for Tracleer (bosentan), treating it as a non-formulary specialty drug. Success requires: 1) Complete Bosentan REMS enrollment for both prescriber and patient, 2) Document failure/intolerance of preferred ERAs (ambrisentan, macitentan), and 3) Submit comprehensive clinical documentation including liver function tests and PAH severity data. If denied, New York's external appeal system offers a meaningful chance of overturn. Start today by verifying your exact Aetna plan formulary and checking REMS enrollment status.

Table of Contents

Plan Types & Coverage Implications

Aetna (CVS Health) operates multiple plan types in New York, each with distinct coverage rules for Tracleer (bosentan):

Commercial Plans (HMO/PPO/EPO): Most require prior authorization through CVS Caremark with step therapy requirements. PPO plans may allow out-of-network specialists, while HMO plans typically require referrals to pulmonology or cardiology.

Medicare Advantage: Follow Part D formulary rules with additional Medicare-specific appeal rights and timelines.

Medicaid Managed Care: Subject to New York Medicaid formulary with state fair hearing options beyond standard appeals.

Note: Always verify your specific plan type on your insurance card, as coverage criteria can vary significantly between products.

Formulary Status & Tier Placement

Tracleer (bosentan) typically appears as a non-formulary or high-tier specialty drug across Aetna (CVS Health) plans:

Coverage Status by Plan Type

Plan Type Formulary Status Tier PA Required Step Therapy
Commercial HMO/PPO Non-formulary Specialty Yes Yes
Medicare Advantage Variable 4-5 Yes Varies
Medicaid Managed Care Covered Specialty Yes Yes

Preferred Alternatives (Step Therapy)

Aetna typically requires trials of these ERAs before approving bosentan:

  • Ambrisentan (Letairis) - often first-line preferred
  • Macitentan (Opsumit) - second-line preferred
  • Sildenafil (Revatio) or tadalafil (Adcirca) as PDE5 inhibitors

Utilization Controls: PA, Step Therapy & Limits

Prior Authorization Requirements

All Aetna (CVS Health) plans require prior authorization for Tracleer with these core criteria:

Clinical Requirements:

  • Confirmed WHO Group I PAH diagnosis with supporting catheterization data
  • NYHA/WHO functional class II-IV symptoms
  • Prescriber specialty: cardiology or pulmonology experience

Safety Requirements:

  • Active Bosentan REMS enrollment for prescriber and patient
  • Baseline and monthly liver function tests documented
  • Monthly pregnancy testing plan for reproductive-age females

Step Therapy Documentation:

  • Prior trials and documented failure/intolerance of preferred ERAs
  • Specific adverse effects or contraindications to alternatives
  • Clinical rationale for bosentan necessity

Quantity Limits

Typical limits include:

  • 62.5 mg tablets: 60 tablets per 30 days
  • 125 mg tablets: 60 tablets per 30 days
  • Exceptions available with clinical justification

Specialty Pharmacy Requirements

Tracleer must be dispensed through CVS Specialty Pharmacy or other REMS-certified pharmacies:

Prescription Setup Process

  1. REMS Enrollment: Complete at BosentanREMSProgram.com or call 866-359-2612
  2. CVS Specialty Enrollment: Submit Tracleer Prescription and Statement of Medical Necessity form
  3. Aetna PA Approval: Required before CVS Specialty can dispense
  4. Patient Onboarding: CVS Specialty contacts patient for delivery coordination

Required Documentation for CVS Specialty

  • Completed Tracleer enrollment form with prescriber signatures
  • Copy of Aetna PA approval
  • Insurance cards (front and back)
  • Lab results and monitoring schedule

Cost-Share Dynamics

Understanding your out-of-pocket costs helps with financial planning:

Commercial Plans: Specialty tier typically requires 25-40% coinsurance after deductible Medicare Plans: Part D specialty tier often $100-400+ monthly copay Medicaid Plans: Usually minimal copay ($1-5) with prior authorization

Financial Assistance Options

  • Janssen CarePath: Call 866-228-3546 for copay support eligibility
  • Patient Assistance Programs: Income-based free drug programs
  • State Programs: New York may offer additional assistance for qualifying residents

Submission Process & Required Documentation

Preferred Submission Method

Submit through Availity provider portal accessing Novologix (Aetna's specialty drug PA system):

  1. Log into Availity
  2. Select Aetna as payer
  3. Choose "Drug Prior Authorization/Specialty Medication PA"
  4. Complete Novologix form with required clinical data

Alternative Submission Options

Required Clinical Documentation

Diagnosis Documentation:

  • ICD-10 codes (I27.0 series for PAH)
  • Right heart catheterization results
  • Echocardiogram findings
  • WHO functional class assessment

Treatment History:

  • Prior ERA trials with specific drugs, doses, durations
  • Documented adverse effects or lack of efficacy
  • Contraindication rationale if no prior trials

Safety Monitoring:

  • Baseline LFTs (ALT, AST, bilirubin) with dates
  • Monthly monitoring schedule
  • Pregnancy testing plan (if applicable)
  • REMS enrollment confirmation numbers

Common Approval Patterns

Successful Tracleer approvals typically include:

Strong Clinical Documentation

  • Specialist notes from experienced PAH clinician
  • Comprehensive hemodynamic data supporting PAH severity
  • Clear functional limitation documentation
  • Evidence-based treatment rationale

Robust Step Therapy Justification

  • Detailed ambrisentan trial: "Patient tried ambrisentan 10mg daily for 12 weeks with inadequate response (6MWT improved only 15 meters) and developed peripheral edema requiring discontinuation"
  • Specific contraindications: "Macitentan contraindicated due to severe hepatic impairment (Child-Pugh B)"

REMS Compliance

  • Active prescriber and patient enrollment numbers
  • Documented baseline labs within 30 days
  • Written monitoring protocol with specific thresholds

Appeals Process: Internal to External Review

Aetna Internal Appeal Process

Timeline: 180 days from denial notice Standard Review: 30 days for decision Expedited Review: 72 hours when health at risk

Required Documentation for Appeal:

  • Copy of original denial letter
  • Point-by-point response to each denial reason
  • Additional clinical evidence addressing gaps
  • Updated specialist letter supporting medical necessity

Provider-Side Appeals

Healthcare providers can file disputes and appeals through:

  • Availity provider portal
  • Written appeal within 180 days
  • Peer-to-peer review requests for complex cases

New York External Review System

If Aetna's internal appeal is unsuccessful, New York offers robust external review rights:

Eligibility for External Review

New York's external appeal program covers denials based on:

  • Medical necessity determinations
  • Experimental/investigational designations
  • Non-formulary drug coverage decisions

External Review Process

Filing Deadline: 4 months from final internal appeal decision Standard Timeline: 30 days for decision Expedited Timeline: 72 hours for urgent cases (24 hours for urgent drug denials) Filing Fee: Maximum $25 (waived for financial hardship or Medicaid)

Required Documentation

  • External appeal request form
  • Copy of Aetna's final internal appeal decision
  • Medical records supporting the request
  • Authorization for record release
  • Physician statement explaining medical necessity

Success Rates and Binding Nature

While New York doesn't publish drug-specific overturn rates, external appeals have meaningful success rates when well-documented. Similar state programs report 30-60% overturn rates for specialty drug denials. External review decisions are binding on Aetna - if overturned, coverage must be provided.

From our advocates: We've seen Tracleer appeals succeed when families gathered comprehensive documentation showing clear functional decline on preferred ERAs and provided month-by-month lab tracking demonstrating safe liver monitoring. The key was addressing each specific denial reason with concrete clinical evidence rather than general medical necessity arguments.

Clinician Corner: Medical Necessity Letter Checklist

Essential Components for Strong Appeals

Problem Statement: "Patient has WHO Group I PAH with NYHA Class III symptoms despite optimal background therapy, experiencing progressive functional decline."

Prior Treatment Documentation:

  • Ambrisentan 10mg daily × 12 weeks: minimal improvement, developed limiting peripheral edema
  • Macitentan contraindicated due to drug-drug interaction with patient's anticoagulation regimen

Clinical Rationale: "Bosentan offers distinct pharmacologic profile with twice-daily dosing allowing better symptom control and established safety profile in this patient's comorbidity context."

Monitoring Commitment: "Monthly LFTs and pregnancy testing per REMS requirements with immediate dose adjustment protocol if abnormalities develop."

Guideline Support: Reference AHA/ESC PAH guidelines supporting ERA therapy escalation.

FAQ

How long does Aetna (CVS Health) prior authorization take in New York? Standard PA decisions typically take 7-14 business days. Expedited reviews are available within 24-72 hours when delay would jeopardize health.

What if Tracleer is non-formulary on my plan? Request a formulary exception with documentation showing why formulary alternatives are inappropriate or ineffective.

Can I continue Tracleer during an appeal? For some Medicaid plans, you may request continuation of benefits during appeal if you file within required timeframes.

Does step therapy apply if I tried ERAs in another state? Yes, documented trials from other providers/states typically satisfy step therapy requirements if adequately documented.

What happens if my liver tests become abnormal? Follow REMS protocol for dose adjustment or discontinuation. Aetna may suspend authorization until labs normalize.

How do I get help with the appeal process in New York? Contact Community Health Advocates at 888-614-5400 for free assistance with insurance appeals.

Counterforce Health helps patients, clinicians, and specialty pharmacies transform insurance denials into successful appeals through automated, evidence-backed documentation. Our platform analyzes denial letters and plan policies to create targeted rebuttals that address specific payer criteria, significantly improving approval rates for complex specialty drugs like Tracleer.

For patients facing Tracleer denials, Counterforce Health's comprehensive approach ensures every appeal addresses Aetna's specific clinical policies while incorporating the robust evidence base supporting bosentan therapy in pulmonary arterial hypertension.

Sources & Further Reading

Disclaimer: This guide provides educational information about insurance coverage and appeal processes. It is not medical advice, legal counsel, or a guarantee of coverage outcomes. Always consult with your healthcare provider about treatment decisions and verify current policy details with your insurance plan. Coverage policies and procedures may change; confirm current requirements with Aetna (CVS Health) and New York regulatory authorities.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.